Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.73 - $11.95 $48,705 - $101,575
8,500 Added 125.0%
15,300 $182,000
Q2 2024

Aug 14, 2024

BUY
$3.96 - $6.93 $1,584 - $2,772
400 Added 6.25%
6,800 $39,000
Q1 2024

May 15, 2024

SELL
$4.33 - $5.75 $21,217 - $28,175
-4,900 Reduced 43.36%
6,400 $33,000
Q4 2023

Feb 14, 2024

BUY
$2.89 - $5.34 $13,872 - $25,632
4,800 Added 73.85%
11,300 $59,000
Q3 2023

Nov 14, 2023

SELL
$2.8 - $4.94 $2,240 - $3,952
-800 Reduced 10.96%
6,500 $21,000
Q2 2023

Aug 14, 2023

BUY
$0.93 - $3.64 $6,789 - $26,572
7,300 New
7,300 $21,000
Q4 2022

Feb 14, 2023

BUY
$1.81 - $8.14 $8,326 - $37,444
4,600 New
4,600 $12,000

Others Institutions Holding BVS

About Bioventus Inc.


  • Ticker BVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 61,664,200
  • Market Cap $658M
  • Description
  • Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral ner...
More about BVS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.